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Identity
Other 
names Aurora A
ARK1
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BTAK
MGC34538
STK15
STK6
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Hugo AURKA
Location 20q13.31
DNA/RNA
Description The gene encompasses 22,8 kb of DNA; 9 Exons.
Transcription 2253 bp mRNA.
Protein
 
Description 403 amino acids, 46kDa protein. At the amino terminal domain, 
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three putative conserved Aurora boxes (A-boxI, A-boxII and 
A-boxIII) can be identified. The functional significance of these 
boxes are not yet clearly known and there is suggestive 
evidence in the literature that these may be involved in 
subcellular localization or substrate recognition for the proteins. 
One of the serine residues in the A-boxII of Aurora-A kinase has 
recently been shown to be involved in the degradation of the 
protein. One activation motif and a destruction box in 
C-terminal. AURKA is regulated by phosphorylation in a cell cycle 
dependent manner. This phosphorylation occurs on a conserved 
residue, threonine 288, within the activation loop of the 
catalytic domain of the kinase and results in a significant 
increase in the enzymatic activity. 
AURKA protein is able to physically associate with multiple 
important cellular proteins such as p53, BRCA1, and TACC1. 
The interactions of AURKA with those critical molecules have 
been shown to disrupt/alter their physiological functions and 
may play roles in tumorigenesis.
Expression Widely expressed, AURKA mRNA and protein expression levels 
are low during G1 and S phase and peak during the G2/M phase 
of the cell cycle. Kinase activity of the protein is also cell cycle 
regulated and the highest activity coincides with the most 
elevated expression level of the protein during mitosis.
Localisation AURKA localizes next to the centrosome late in the G1 phase 
and early in the S phase. As the cell cycle progresses, 
concentration of AURKA increases and the kinase associates 
with the mitotic poles and the adjacent spindle microtubules. 
AURKA remains associated with the spindles through telophase.
Function Serine/threonine kinase identified as key regulator of the 
mitotic cell division process. Known to be involved in the 
regulation of centrosome function, bipolar spindle assembly and 
chromosome segregation processes. AURKA is critical for 
proper formation of mitotic spindle. It is required for the 
recruitment of several different proteins important to the 
spindle formation. Among these target proteins are TACC, a 
microtubule-associated protein that stabilizes centrosomal 
microtubules and Kinesin 5, a motor protein involved in the 
formation of the bipolar mitotic spindle. Two upstream 
regulators of AURKA, Ajuba and targeting protein for Xklp2 ( 
TPX2 ) are known. TPX2 is a MT-binding protein involved in 
spindle pole formation and is the best characterized 
RanGTP-dependent spindle activator. TPX2 is required for 
AURKA binding to spindle MTs and its binding to AURKA holds 
the latter in an active conformation. Ajuba and AURKA interact 
in mitotic cells and become phosphorylated. In vitro analyses 
revealed that Ajuba induces the autophosphorylation and 
consequent activation of AURKA. Depletion of Ajuba prevented 
activation of AURKA at centrosomes in late G2 phase and 
inhibited mitotic entry. 
AURKA induces p53 degradation by phosphorylation of 
Ser-315. It was demonstrated that DNA binding and 
transactivation activity of p53 was abrogated by AURKA. 
AURKA phosphorylates p53 at Ser-215 in vitro and in vivo. The 
inhibition of p53 DNA binding and transactivation activity by 
AURKA depends on phosphorylation of Ser-215 but not 
Ser-315. Further, AURKA phosphorylation of Ser-215 of p53 is 
associated with AURKA -regulated cell cycle progression, cell 
survival, and transformation. The p53 is a physiological 
substrate of AURKA and that AURKA exerts its function 
through phosphorylation of Ser-215 of p53.
Homology Aurora related kinases, AURKA and AURKB are present in 
Drosophila,C.elegans and X. laevis. Among mammals, three 
members of the family, AURKA, -B and -C have so far been 
identified. The three members of the mammalian kinases of 
varying peptide lengths share similar catalytic domains located 
in the carboxyl terminus but their amino terminal extensions are 
of variable length and display little or no similarity. By 
examination of the AURKA cDNA sequence the threonine at 
residue 288 in the catalytic domain was found to be highly 
conserved in all Aurora family members as well as in various 
other serine/threonine kinases.
Mutations
Germinal No germline mutations have been reported.
Somatic Recent studies have demonstrated the overexpression and 
amplification of AURKA in many malignant human cancers and 
cell lines including breast, ovarian, colon, prostate, and 
neuroblastoma cancer cell lines. AURKA overexpression induces 
supernumerary centrosomes aneuploidy and cells 
transformation. It has been also reported that ectopic 
overexpression of AURKA in NIH3T3 and immortalized Rat1 
induces cells transformation that generates tumor when 
implanted in nude mice. Elevated AURKA expression amplification 
overrides the checkpoint mechanism that monitors mitotic 
spindle assembly, inducing resistance to the chemotherapeutic 
agent paclitaxel. Cells overexpressing Aurora-A inappropriately 
enter anaphase despite defective spindle formation, and the 
persistence of MAD2 at the kinetochores, marking continued 
activation of the spindle assembly checkpoint. These findings 
suggest that enhanced AURKA expression causes resistence to 
apoptosis induced by mitotic inhibitors in human cancer cells.
Implicated in
Entity Breast cancer
Disease Breast cancer is the most common cause of cancer in women 
and the second most common cause of cancer death in 
women. Some of the patients are hereditary, with a large 
proportion characterized by mutation in BRCA1 and/or BRCA2 
genes.
Oncogenesis The protein level of AURKA is increased at the G2 to M phase 
transition in normal cells, where AURKA is specifically localised 
at centrosomes and mitotic spindles. By contrast, analysis of 
tumour cells of the breast for AURKA expression patterns 
shows that overexpression of AURKA was present in 94% of 
the cases, regardless of their cell-cycle phases, and is diffusely 
detected in the cytoplasm. Amplification of AURKA has been 
detected at higher frequency in tumors from BRCA1 and 
BRCA2 mutation carriers than in sporadic breast tumors, 
suggesting that overexpression of AURKA and inactivation of 
BRCA1 and BRCA2 cooperate during tumor development and 
progression. The F31I polymorphism in AURKA has been 
associated with breast cancer risk in the homozygous state in 
prior studies. Studies have demonstrated that AURKA 
overexpression contributes to genetic instability and 
tumourigenesis by disrupting the proper assembly of the 
mitotic checkpoint complex and occurs in a high proportion of 
breast cancers.
  
Entity Pancreatic cancer
Disease Pancreatic ductal adenocarcinoma is one of the most fatal 
malignancies. Intensive investigation of molecular pathogenesis 
might lead to identifying useful molecules for diagnosis and 
treatment of the disease.
Oncogenesis Pancreatic ductal adenocarcinoma harbors complicated 
aberrations of alleles including losses of 1p, 6q, 9p, 12q, 17p, 
18q, and 21q, and gains of 8q and 20q. Pancreatic cancer is 
usually initiated by mutation of KRAS and aberrant expression 
of SHH. Overexpression of AURKA mapping on 20q13.2 may 
significantly enhance overt tumorigenesity. AURKA was a direct 
downstream target of MAPK1, suggesting that the 
overexpression of AURKA without gene amplification may be 
induced by constitutive activation of MAPK1 in cancer cells. 
The constitutive activation of MAPK1 is frequently observed in 
pancreatic cancer.
  
Entity Ovarian cancer
Disease Ovarian cancer is the most lethal gynecologic malignancy in 
developed countries. The exact cause is usually unknown. The 
risk of developing ovarian cancer appears to be affected by 
several factors.
Oncogenesis Recent studies have shown that DNA gains of the 
chromosomal region 20q13 and overexpression of the 
centrosomal kinase AURKA, the gene of which is found within 
the 20q13 region, are hallmarks of ovarian cancer. 
Amplification of AURKA has been reported in ovarian tumors, 
suggesting a role in ovarian cancer pathology. AURKA is 
polymorphic with two single nucleotide substitutions (449t/a 
and 527g/a) in evolutionarily conserved regions causing amino 
acid changes (F31I and V57I). Two other nucleotide 
substitutions (287c/g and 1891g/c) of unknown significance 
are in 5' and 3' untranslated regions (UTR), respectively. 
AURKA overexpression represented a survival factor for tumor 
cells and a negative prognostic molecular marker.
  
Entity Human esophageal squamous cell carcinoma
Disease Human esophageal squamous cell carcinoma (ESCC) is one of 
the most frequent malignancies worldwide and occurs at a very 
high frequency in the People's Republic of China, South Africa, 
France, and Italy. A number of epidemiological investigations 
have shown that esophageal carcinogenesis and the malignant 
development of esophageal cancers are complex and 
associated with multiple etiologic factors, including genetic 
backgrounds, environmental stimuli, nutritional conditions, and 
cultural habits.
Oncogenesis Despite some epidemiological observations, the biological 
mechanism(s) that is involved in ESCC occurrence and 
progression remains to be elucidated. It has been shown that 
point mutations of the tumor suppressor gene p53 are 
detected in 40% of human esophageal cancers. The Rb gene is 
also frequently mutated in ESCC. Amplification of the cellular 
protooncogenes Myc, EGFR, HST1, INT2, and cyclin D1 are 
often found in this malignant disease. A recent demonstration 
indicates that AURKA polymorphisms are associated with 
advanced disease status of ESCC, and there are strong 
evidence that AURKA is overexpressed in human ESCC and may 
play a role in carcinogenesis and malignancy development of 
ESCC.
  
Entity Human Bladder Cancer
Disease Bladder tumors are among the most common human cancers, 
with approximately 55 000 new cases detected each year in 
the United States. Bladder cancers, which represent a group of 
tumors with diverse morphologic and clinical behavior, exhibit 
one of the strongest relationships seen in any cancer between 
clinical aggressiveness and degree of aneuploidy.
Oncogenesis Bladder cancers arise from at least two distinct, albeit 
sometimes overlapping, pathways that lead to the 
development of papillary and solid or nonpapillary tumors. Most 
superficially growing, low-grade papillary lesions are diploid or 
near-diploid. Although they often recur, they are unlikely to 
invade the bladder wall and metastasize. By contrast, virtually 
all nonpapillary tumors are highly aneuploid and have a strong 
propensity to invade the stroma and metastasize. Superficial 
bladder tumors that are aneuploid are also likely to progress to 
invasive clinically aggressive carcinomas, which may 
metastasize. AURKA amplification is frequently overexpressed 
in bladder tumors tested by FISH and the strong association of 
the gene amplification and overexpression levels with the 
degree of aneuploidy suggests that AURKA may play an 
important role in bladder carcinogenesis by contributing to the 
development of aneuploid cell populations with aggressive 
phenotypes.
  
Entity Human colon cancer
Disease It is the third most common form of cancer and the second 
leading cause of cancer-related death in the Western world. 
Colorectal cancer causes 655,000 deaths worldwide per year, 
including about 16,000 in the UK, where it is the second most 
common site (after lung) to cause cancer death. The most 
common colon cancer cell type is adenocarcinoma which 
accounts for 95% of cases. Other, rarer types include 
lymphoma and squamous cell carcinoma. Adenocarcinoma is a 
malignant epithelial tumor, originating from glandular 
epithelium of the colorectal mucosa. It invades the wall, 
infiltrating the muscularis mucosae, the submucosa and 
thence the muscularis propria.
Oncogenesis Colorectal cancer is a disease originating from the epithelial 
cells lining the gastrointestinal tract. Hereditary or somatic 
mutations in specific DNA sequences, among which are 
included DNA replication or DNA repair genes and also the APC, 
K-Ras, NOD2 and p53 genes, lead to unrestricted cell division. 
Furthermore, genetic instability is expressed in colon cancer by 
an increased rate of a number of different genetic alterations. 
These different manifestations of genetic instability are 
classified into two major categories. The first one involves 
subtle changes in DNA sequences typically represented by 
microsatellite instability (MIN). The second one is characterized 
by gains and losses of whole or parts of chromosomes, named 
chromosomal instability (CIN), and it is considered a driving 
force for tumourigenesis. MIN occurs in approximately 15% of 
colon cancers and results from inactivation of the mismatch 
repair (MMR) system by either MMR gene mutations or 
hypermethylation of the MLH1 promoter. The mechanisms 
inducing CIN in cancer and more specifically in colon cancer are 
only partly understood. At least two possible causes, not 
mutually exclusive, could be responsible for CIN: mutations in 
genes encoding mitotic regulators, such as spindle checkpoint 
proteins, and defects in genes controlling centrosome 
homeostasis. The presence of mutations of the mitotic 
checkpoint regulators BUB1 and BUBR1 and amplification of 
AURKA in a subset of human colon cancers have suggested 
that CIN results primarily from deregulation of DNA replication 
and mitotic-spindle checkpoints.
  
Entity Human Multiple myeloma
Disease Multiple myeloma (also known as MM, myeloma, plasma cell 
myeloma, or as Kahler's disease after Otto Kahler) is a type of 
cancer of plasma cells which are immune system cells in bone 
marrow that produce antibodies. Myeloma is regarded as 
incurable, but remissions may be induced with steroids, 
chemotherapy, thalidomide and stem cell transplants. Myeloma 
is part of the broad group of diseases called hematological 
malignancies. Multiple myeloma (MM) is a malignancy 
characterized by genetic instability, suggesting a disruption of 
checkpoints that arrest cells at G2M when injury to the mitotic 
machinery occurs.
Oncogenesis The expression of RHAMM and other centrosome-associated 
genes are known to correlate with the extent of centrosome 
amplification in multiple myeloma, and with poor prognosis. 
RHAMM has a significant interaction with TPX2, a protein which 
regulates the localization and action of AURKA at the spindle 
poles. AURKA is expressed ubiquitously in myeloma, to varying 
degrees. Aurora kinase inhibitor VE-465 also induces apoptosis 
and death in myeloma cell lines and primary myeloma plasma 
cells. The combination of VE-465 and dexamethasone 
improves cell killing compared with the use of either agent 
alone, even in cells resistant to the single agents.
  
Entity Human hepatocellular carcinoma
Disease Hepatocellular carcinoma (HCC, also called hepatoma) is a 
primary malignancy (cancer) of the liver. Most cases of HCC are 
secondary to either a viral hepatitide infection (hepatitis B or 
C) or cirrhosis (alcoholism being the most common cause of 
hepatic cirrhosis). In countries where hepatitis is not endemic, 
most malignant cancers in the liver are not primary HCC but 
metastasis (spread) of cancer from elsewhere in the body, e.g. 
the colon. Treatment options of HCC and prognosis are 
dependent on many factors but especially on tumor size and 
staging.
Oncogenesis AURKA is overexpressed frequently in HCC, and correlated with 
high grade and high stage, indicating that overexpression of 
AURKA plays a role in the development and progression of HCC. 
Furthermore in HCC is frequently associated the homozygous 
deletion of p15E2 ( MTS2/INK4b/CDKN2B ) and p16E2 ( 
MTS1/INK4a/CDKN2A ) with overexpression of AURKA gene, 
this association may play a role in the oncogenesis and 
malignant progression of HCC.
  
Entity Human Upper gastrointestinal adenocarcinomas
Disease Upper gastrointestinal adenocarcinomas are the second most 
common cause of cancer-related death in the world. and are 
characterized by complex molecular changes. Several 
epidemiological studies have indicated that the incidence of 
proximal adenocarcinomas of the gastroesophageal junction 
and lower esophagus is rising faster than ever before in the 
Western world. The incidence of adenocarcinoma of the cardia, 
gastroesophageal junction, and lower esophagus has been 
rapidly rising, 5-fold to 6-fold in the past few decades, 
especially in patients younger than 50 years of age.
Oncogenesis Overexpression of AURKA is frequent in upper gastrointestinal 
adenocarcinomas and in recently works it was identified the 
AURKA/AKT axis as an important mechanism that provides 
cancer cells with potent antiapoptotic properties through 
regulating p53-dependent apoptosis. Frequent overexpression 
of AURKA at the mRNA and protein levels in upper 
gastrointestinal adenocarcinomas, and interestingly, this 
overexpression was more prevalent in gastroesophageal 
junction adenocarcinomas andlower esophageal, Barrett-related 
adenocarcinomas (BAs) than in antrum and body gastric 
adenocarcinomas. There are not an association between 
AURKA overexpression and histopathological paramters such 
as tumor grade, TNM classification, and lymph-node 
metastasis.
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